Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kava Prohibition One Of Five Options Outlined In MCA Consultation Document

This article was originally published in The Tan Sheet

Executive Summary

A permanent prohibition on the sale of kava is the favored of a series of options reviewed in a consultation document released by the UK's Medicines Control Agency July 25
Advertisement

Related Content

Chattem Exiting Ephedra Market With Dexatrim Reformulations
Chattem Exiting Ephedra Market With Dexatrim Reformulations
Chattem Exiting Ephedra Market With Dexatrim Reformulations
Kava Removed From UK Market; FDA Contacts Healthcare Community
Kava Safety Reconsidered In Germany, FDA/Trade Associations Take Note
Kava Safety Reconsidered In Germany, FDA/Trade Associations Take Note

Topics

Advertisement
UsernamePublicRestriction

Register

PS094334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel